Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of JNJ-67670187 in Healthy Participants
NCT03723746Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2018
- Primary completion
- Dec 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of VE202 in ulcerative colitis (UC) and inflammatory bowel disease (IBD) (9 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Treatment Emergent Adverse Events and Serious Adverse Events at Day 98 and Abnormalities in Vital Signs, Physical Examinations, Electrocardiogram, and Clinically Significant Laboratory Findings. Started Oct 2018; status: completed.
02
Drugs
VE202
03
Conditions
ulcerative colitis (UC)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03723746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03723746.